Please login to the form below

Not currently logged in

Breo off to slow start in US as Advair slips, says GSK

And China issues continue to affect sales performance
GSK - logo on building

Pressure on sales in the US and China caused a 13 per cent decline in revenues at GlaxoSmithKline (GSK) in the first quarter, compounded a slow take-up for new respiratory drug Breo.

Competition for GSK's biggest-selling drug Advair (salmeterol and fluticasone) for asthma and chronic obstructive pulmonary disease (COPD) was a key factor in the decline, with downwards pricing pressure and delisting from the formularies of some pharmacy benefits managers in the US.

Breo (vilanterol and fluticasone) is a direct successor to Advair and was approved in the US last year, but GSK chief executive Sir Andrew Witty told investors yesterday that the new drug had "started a bit slower than we would have liked."

First-quarter turnover came in at £5.6bn ($9.5bn), with Advair sliding 15 per cent to £1.04bn - dragging down US sales by 10 per cent - while Breo (known as Relvar in some markets) added just £3m to the pot since its launch in the US in the fourth quarter. Profits at GSK also went on the slide, coming in at £668m compared to £961m a year earlier.

Witty put the lacklustre performance of Breo down to slow introduction of reimbursement coverage in the US, although he noted that Medicare Part D coverage for the new product was now running at 70 per cent, up from 3 per cent on January 1.

GSK's respiratory franchise will also get a boost from the launch of combination COPD therapy Anoro (umeclidinium and vilanterol) and also monotherapy Incruse (umeclidinium), which has just been approved in the US and Europe.

"For many people in the outside of the company, there is great focus on the apparent reliance of GSK on Advair," commented Witty. "Clearly Advair had a difficult quarter… yet the group delivered 2 per cent earnings per share growth," he added.

Quarterly turnover in China was also down 20 per cent to £137m on the back of the ongoing corruption investigation, although GSK did manage a 2 per cent rise in emerging markets turnover overall.

Not interested in AZ offer

Witty also downplayed any suggestion that GSK might be interested in a counter-offer for AstraZeneca - currently facing an unsolicited £60bn takeover offer from Pfizer - telling investors he was unconvinced by the merits of megamergers in the pharma sector and did not want GSK to be diverted from its "core R&D business".

He also pointed out that an offer would be disruptive as GSK has just announced a major asset swap deal with Novartis that Witty said would "surgically enhance" its vaccines and the consumer health businesses.

Article by
Phil Taylor

1st May 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Hamell - Cake

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...